Current Rheumatology Reports

Current Rheumatology Reports is a hybrid, invitation-only review journal published by Springer that has surveyed recent rheumatology research since 1999, with a 2025 Journal Impact Factor of 4.9.《当代风湿病学报告》（Current Rheumatology Reports）是一份由施普林格（Springer）出版的混合型邀稿综述期刊，1999 年创刊，专事梳理风湿病学领域的最新研究，2025 年期刊影响因子为 4.9。

Scope

• The journal reviews the most important and recently published research in rheumatology, aiming to serve everyone involved in the care and prevention of rheumatic disease.刊物评述风湿病学领域最重要且新近发表的研究，服务于风湿病诊疗与预防的各相关方。
• Coverage is organised by section, beginning with the major forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus.内容按学科分部组织，首先是各类主要关节炎、骨质疏松与代谢性骨病以及系统性红斑狼疮。
• Further sections address antiphospholipid syndrome, autoinflammatory disorders, vasculitis, inflammatory muscle disease, and pediatric rheumatology.其他分部涉及抗磷脂综合征、自身炎症性疾病、血管炎、炎性肌病与儿童风湿病学。
• Crystal arthritis, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, and spondyloarthritis each have a dedicated section.晶体性关节炎、骨关节炎、银屑病关节炎、类风湿关节炎与脊柱关节炎各设专门分部。
• Chronic pain, imaging, surgery and perioperative care, the microbiome, complementary and integrative medicine, and artificial intelligence and technology are also covered.慢性疼痛、影像学、外科与围手术期管理、微生物组、补充与整合医学以及人工智能与技术同样在覆盖之列。
• Reviews stress new developments and recently published papers of major importance, supported by annotated reference lists, and occasional commentaries highlight the views of leading figures.综述着重介绍新进展与近期发表的重要论文，并附注释文献表；刊物还不定期刊登知名学者的评论文章。

History

• The journal was founded in 1999 by Current Science Inc. of Philadelphia, and Volume 1, Number 1 appeared in October 1999.刊物于 1999 年由费城的 Current Science 公司（Current Science Inc.）创办，第一卷第一期于 1999 年 10 月出版。
• Springer acquired the Current Medicine Group, the parent of Current Science Inc., in 2005, and the title has since been published within Springer.2005 年，施普林格收购了 Current Science 公司的母公司当代医学集团（Current Medicine Group），该刊此后归入施普林格出版。
• It appeared in six issues a year until 2012 and monthly from 2013 through 2024, before moving to continuous publication with a single annual volume in 2025, when Volume 27 carried one issue.刊物在 2012 年以前每年出版 6 期，2013 年至 2024 年按月出版，自 2025 年起改为连续出版、每年一卷一期，当年为第 27 卷。
• The journal is hybrid, with subscription access and an open-access option for individual articles.刊物采用混合模式，以订阅阅读为主，单篇论文可选择开放获取。
• Its 2025 Journal Impact Factor is 4.9, compared with 3.9 in 2024, 4.686 in 2022 and 4.592 in 2021, and the five-year figure for 2025 is 5.7.2025 年期刊影响因子为 4.9，2024 年为 3.9，2022 年为 4.686，2021 年为 4.592；2025 年的五年影响因子为 5.7。
• It ranks 11th of 58 journals in rheumatology, and Springer reports a median of five days from submission to first decision.刊物在风湿病学类 58 种期刊中排名第 11，施普林格公布的从投稿到首次决定中位时间为 5 天。
• It is indexed in Science Citation Index Expanded, Scopus, MEDLINE/PubMed, EMBASE, and Chemical Abstracts.刊物被科学引文索引扩展版、Scopus、MEDLINE/PubMed、EMBASE 与化学文摘收录。

Editors

• Bruce N. Cronstein, Paul R. Esserman Professor of Medicine at NYU Langone Health and director of its Clinical and Translational Science Institute, is Editor-in-Chief.主编为布鲁斯·N·克罗斯坦（Bruce N. Cronstein），纽约大学朗格尼医学中心保罗·R·埃瑟曼医学教授、临床与转化科学研究所所长。
• Some twenty section editors, each an authority in a defined area, commission the review topics.约 20 位分部编辑各自主持一个既定领域并负责约请综述选题。
• They include Seza Ozen (pediatric rheumatology, Hacettepe University), Larry W. Moreland (rheumatoid arthritis, University of Colorado), Vasileios C. Kyttaris (lupus, Beth Israel Deaconess Medical Center), and Alexandre Wagner Silva de Souza (vasculitis, Federal University of Sao Paulo).其中包括塞扎·厄曾（Hacettepe University，儿童风湿病学）、拉里·W·莫兰（University of Colorado，类风湿关节炎）、瓦西莱奥斯·C·基塔里斯（Beth Israel Deaconess Medical Center，狼疮）与亚历山大·瓦格纳·席尔瓦·德索萨（Federal University of Sao Paulo，血管炎）。
• An international editorial board of about twenty members, from the United States, Europe, Japan, India, Nigeria, Canada, and Australia, reviews the annual table of contents.由约 20 位成员组成的国际编委会来自美国、欧洲、日本、印度、尼日利亚、加拿大与澳大利亚，负责审议年度目录。
• Because the journal is invitation-only, topics are selected by section editors rather than by unsolicited submission, and there is no pre-submission enquiry route.由于刊物仅接受邀稿，选题由分部编辑确定而非作者自由投稿，也不设投稿前咨询渠道。
• Invited manuscripts are peer reviewed, and the journal added a section on artificial intelligence and technology to track methods entering rheumatology practice.受邀稿件仍须经过同行评审；刊物新设人工智能与技术分部，以追踪进入风湿病诊疗实践的新方法。